Commercial

Meet the 2018 Women to Watch Honorees

Meet the 2018 Women to Watch Honorees

MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.

MM&M Hall of Femme 2018: The profiles

MM&M Hall of Femme 2018: The profiles

MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.

Allergan's Botox sets its sights on a new customer: men

Allergan's Botox sets its sights on a new customer: men

By

Botox Cosmetic has rolled out its first ad campaign focused on reaching male customers.

Cannabis gets the iPhone treatment

Cannabis gets the iPhone treatment

By

Thanks to legalization, a new breed of startups are changing the nature of cannabis advertising.

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

A tale of two lung cancer immunotherapies: Merck's Keytruda takes the reins

By

Opdivo's commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.

Dr. Jessica Grossman, Medicines360

Dr. Jessica Grossman, Medicines360

Dr. Jessica Grossman is CEO of Medicines360.

Pro ad report 2017: Ad revenue plunged for print-first publishers

Pro ad report 2017: Ad revenue plunged for print-first publishers

The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?

Amarin's Salyer preps for Vascepa push

Amarin's Salyer preps for Vascepa push

By

Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

By

Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.

How Aubagio became the most switched-to oral MS drug

How Aubagio became the most switched-to oral MS drug

By

Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force

Why haven't biosimilars gained ground in the U.S.?

Why haven't biosimilars gained ground in the U.S.?

By

Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?

Five things for pharma marketers to know: Monday, October 23, 2017

Five things for pharma marketers to know: Monday, October 23, 2017

By

Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine

Merck to axe 1,800 sales positions, form new chronic-care sales team

Merck to axe 1,800 sales positions, form new chronic-care sales team

By

The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.

Top 25 women's health brands, based on U.S. sales in 2016

Top 25 women's health brands, based on U.S. sales in 2016

By

Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.

Infographic | The leaders of the global hepatitis-C market

Infographic | The leaders of the global hepatitis-C market

By

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Top 25 vaccine products in 2016, based on U.S. sales

Top 25 vaccine products in 2016, based on U.S. sales

By

Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.

Horizon CEO Tim Walbert knows patients because he is one

Horizon CEO Tim Walbert knows patients because he is one

He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.

Study: Hiking the prices of heart drugs led to fewer sales

Study: Hiking the prices of heart drugs led to fewer sales

By

Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

By

What's holding back value-based pricing deals from moving beyond the pilot phase?

Pharma companies, now marketing high-science drugs, rely more on medical affairs

Pharma companies, now marketing high-science drugs, rely more on medical affairs

By

Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.

Five things for pharma marketers to know: Friday, August 4, 2017

Five things for pharma marketers to know: Friday, August 4, 2017

By

AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch

Novartis' CAR-T therapy gets nod from FDA committee

Novartis' CAR-T therapy gets nod from FDA committee

By

The drugmaker is one step closer to a potential approval of its experimental cancer treatment.

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

By

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.

Five things for pharma marketers to know: Monday, June 5, 2017

Five things for pharma marketers to know: Monday, June 5, 2017

By

Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

By By

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

By

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

By

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

Five things for pharma marketers to know: Friday, March 24, 2017

Five things for pharma marketers to know: Friday, March 24, 2017

By

Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant beefs up Salix salesforce, to relaunch Addyi

By

Valeant added 250 primary care sales reps to promote its Salix portfolio.